LSTM plays a unique role in the response to COVID-19. It partners with multiple institutions and organisations aimed to have immediate benefits for public health in the UK and overseas.
Within LSTM a lot of research is conducted via the Centre for Drugs and Diagnostics (CDD). This centre comprises an experienced multi-disciplinary group of experts working together researching, developing and validating drugs and diagnostics in response to the COVID-19 pandemic. It uses state-of-the art laboratories and equipment and works closely with industry, NHS and academia.
LSTM also partners with multiple other institutions and organisations to provide evidence based advisory services to government departments and other interested parties.
In addition, LSTM, the University of Liverpool (UoL) and the NHS, represented by Liverpool Health Partners (LHP), have united to redirect the majority of Liverpool's research efforts to COVID-19. The research programmes are designed to have immediate benefits for public health and are supported by £1.1 million in pump priming from LSTM and the University of Liverpool and the efforts of over 200 researchers, underpinned by equipment and laboratory space across the Liverpool City Region.
The Centre of Excellence in Infectious Diseases Research (CEIDR), its industry arm CEIDR Innovations, and the Health Protection Research Unit in Emerging Zoonotic Infections (HPRU EZI), both established LSTM and UoL initiatives, are working together to deliver an ambitious and innovative programme of work.
Funding has been awarded to 21 projects across LSTM and the University of Liverpool in response to COVID-19, working with the NHS and industry.